Free Trial
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Inovio Pharmaceuticals logo
$1.44 -0.71 (-32.94%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$1.43 0.00 (-0.28%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Key Stats

Today's Range
$1.30
$1.54
50-Day Range
$1.44
$2.27
52-Week Range
$1.30
$12.33
Volume
21.09 million shs
Average Volume
731,225 shs
Market Capitalization
$52.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75
Consensus Rating
Moderate Buy

Company Overview

Inovio Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

INO MarketRank™: 

Inovio Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 231st out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Inovio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Inovio Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.23) to ($2.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inovio Pharmaceuticals is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inovio Pharmaceuticals is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inovio Pharmaceuticals has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Inovio Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    17.75% of the float of Inovio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inovio Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving.
  • Dividend Yield

    Inovio Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Inovio Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.75% of the float of Inovio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inovio Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving.
  • News Sentiment

    Inovio Pharmaceuticals has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Inovio Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    26 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.30% of the stock of Inovio Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

  • Read more about Inovio Pharmaceuticals' insider trading history.
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INO Stock News Headlines

Inovio Pharmaceuticals Stock Falls After Pricing Offering
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
INOVIO Announces Pricing of $25 Million Public Offering
Inovio Pharma Shares Slide on Plans for Public Offering
INOVIO Announces Proposed Public Offering
See More Headlines

INO Stock Analysis - Frequently Asked Questions

Inovio Pharmaceuticals' stock was trading at $1.83 at the start of the year. Since then, INO shares have decreased by 21.6% and is now trading at $1.4350.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.23. The biopharmaceutical company earned $0.07 million during the quarter, compared to analyst estimates of $0.01 million.
Read the conference call transcript
.

Shares of Inovio Pharmaceuticals reverse split on the morning of Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
5/13/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:INO
Employees
320
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$18.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+579.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$107.25 million
Pretax Margin
-34,091.52%

Debt

Sales & Book Value

Annual Sales
$220 thousand
Price / Cash Flow
N/A
Book Value
$1.90 per share
Price / Book
0.76

Miscellaneous

Free Float
35,830,000
Market Cap
$52.62 million
Optionable
Optionable
Beta
1.31

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:INO) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners